

Certificate of Analysis

Print Date: Jan 14th 2016

www.tocris.com

Product Name: PF 4778574 Catalog No.: 4900 Batch No.: 1

CAS Number: 1219633-99-4

IUPAC Name: N-[(3R,4S)-3-[4-(5-cyano-2-thienyl)] retrahydro-2H-pyran-4-yl]-2-propanesulfonamide

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: $C_{19}H_{22}N_2O_3S_2$

Batch Molecular Weight: 390.52
Physical Appearance: White solid

Solubility: DMSO to 100 mM

ethanol to 50 mM

Storage: Store at +4°C

Batch Molecular Structure:

2. ANALYTICAL DATA

HPLC: Shows 99.9% purity

¹H NMR: Consistent with structure Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

Theoretical 58.44 5.68 7.17 Found 58.29 5.67 7.28



Product Information

Print Date: Jan 14th 2016

www.tocris.com

Product Name: PF 4778574 Catalog No.: 4900 Batch No.: 1

CAS Number: 1219633-99-4

IUPAC Name: N-[(3R,4S)-3-[4-(5-cyano-2-thienyl)phenyl]tetrahydro-2H-pyran-4-yl]-2-propanesulfonamide

Description:

Positive allosteric modulator of AMPA receptors ($K_i = 85 \text{ nM}$). Prevents ketamine-induced working memory impairments. Brain penetrant.

Physical and Chemical Properties:

Batch Molecular Formula: $C_{19}H_{22}N_2O_3S_2$ Batch Molecular Weight: 390.52

Physical Appearance: White solid

Minimum Purity: >98%

Batch Molecular Structure:

Storage: Store at +4°C

Solubility & Usage Info:

DMSO to 100 mM ethanol to 50 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Roberts *et al* (2010) Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction. Behav.Brain Res. *212* 41. PMID: 20347881.

Doran et al (2012) An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations. Drug Metab.Dispos. **40** 2162. PMID: 22899853.

Shaffer *et al* (2013) Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574. J.Pharmacol.Exp.Ther. **347** 212. PMID: 23899905.